Pricing
  1. US-listed companies
  2. U.S. Stem Cell, Inc.
  3. Financials
  4. Gross profit

U.S. Stem Cell, Inc.【USRM】

Market cap
$64.15K
P/E ratio
SummaryFinancials
Period EndGross profit (Million USD)YoY (%)
Dec 31, 20220-60.81%
Dec 31, 20210-30.17%
Dec 31, 20200-95.36%
Dec 31, 20185+26.28%
Dec 31, 20174+72.18%
Dec 31, 20162+73.31%
Dec 31, 20151+55.59%
Dec 31, 20131+9.09%
Dec 31, 20121+9.13%
Dec 31, 20111

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)